CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL).

Autor:	Khouja, M., Genuardi, E., Ferrero, S., Alessandria, B., Verhagen, O. J., Homburg, C., van der Velden, V. H., Gameiro, P., Sanz, R. García, Herrera, A. Medina, Fronkova, E., Brüggemann, M., Dreyling, M., Hoster, E., Ladetto, M., Langerak, A. W., Darzentas, N., Pal, K., Stewart, P. J., Gonzalez de Castro, D.
Předmět:	CELL-free DNA CIRCULATING tumor DNA TUMOR genetics CELLULAR therapy MANTLE cell lymphoma SINGLE nucleotide polymorphisms
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p181-183, 3p
Abstrakt:	Cell-free (cf)DNA captures tumor genetics and can be used to assess disease kinetics and minimal residual disease (MRD). B Introduction: b The European MCL Network trial TRIANGLE (NCT02858258) evaluated the addition of ibrutinib to standard treatment with autologous stem cell transplantation (ASCT) (arm A+I) in comparison to ASCT alone (arm A) and ibrutinib plus chemoimmunotherapy without ASCT (arm I) demonstrating significant and clinically relevant superiority of additional ibrutinib on outcome. CELL-FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL). [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text